Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety Evaluation of IBI308 in Patients With Relapsed/Refractory Extranodal NK/T Cell Lymphoma, Nasal Type: a Multicenter, Single Arm, Phase 2 Study (ORIENT-4)

Trial Profile

Efficacy and Safety Evaluation of IBI308 in Patients With Relapsed/Refractory Extranodal NK/T Cell Lymphoma, Nasal Type: a Multicenter, Single Arm, Phase 2 Study (ORIENT-4)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sintilimab (Primary)
  • Indications Extranodal NK-T-cell lymphoma
  • Focus Therapeutic Use
  • Acronyms ORIENT-4
  • Sponsors Innovent Biologics
  • Most Recent Events

    • 04 Jun 2019 Results (The data cutoff was February 2, 2019 ) presented in an Innovent Biologics Media Release.
    • 04 Jun 2019 Results (data cutoff; 2 Feb 2019) assessing Sintilimab for replapsed/refractory extranodal NK/T-cell lymphoma published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
    • 15 May 2019 According to a Eli Lilly media release, data from this trial will be presented at the upcoming 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31-June 4, 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top